Salute e Benessere

T-knife Therapeutics Appoints Christoph Broja to its Board of Directors

SAN FRANCISCO and BERLIN, July01, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced the appointment of Christoph Broja, a Partner at EQT Life Sciences, to its Board of Directors.“We are pleased to welcome Christoph to our board of directors,” stated Thomas M. Soloway, President and Chief Executive Officer. “Christoph brings a wealth of experience and insight...
Nasdaq GlobeNewswire
01/07/2025

Genmab Announces Changes to its Executive Committee

Media ReleaseCOPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/SGreg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 Genmab A/S (Nasdaq:GMAB)announced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will retire from Genmab after a successful tenure that spanned 23 years with the company...
Nasdaq GlobeNewswire
01/07/2025

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli®…

Aspaveli/EMPAVELI is approved in the European Union, other countries globally, and the US for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia, a rare blood disorder. It is currently under review in the European Union and the U.S. for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare kidney diseases. An opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products…
PR Newswire
01/07/2025

Preliminary revenue figures for the 2024/25 financial year

ANNOUNCEMENT NO. 290 1 July 2025 Preliminary revenue figures for the 2024/25 financial yearBased on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million for the financial year 2024/25, against the previously announced DKK 470-490 million.ChemoMetec’s annual report for 2024/25 is scheduled to be released on 11 September 2025. Additional information Martin Helbo Behrens, CEO Tel.: (+45) 48 13 10 20Kim Nicolajsen, CFO Tel.: (+45) 48 13 10 20...
Nasdaq GlobeNewswire
01/07/2025

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly…

Acromegaly is a rare, serious, and chronic disease characterized by excessive growth of bone and tissue, resulting in enlarged hands, feet, facial features, and inner organs. Symptoms include fatigue, joint pain, headache, visual field defects, excessive sweating, and paresthesia.2 Patients with uncontrolled acromegaly often experience reduced quality of life and increased mortality risk.3,4 An estimated 70,000 people in the EU are living with acromegaly.5 Acromegaly is a rare, serious, and...
PR Newswire
01/07/2025

Alvotech and Advanz Pharma Enter into European Supply and Commercialization…

REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10,...
Nasdaq GlobeNewswire
01/07/2025

Implantica announces publication of the landmark RefluxStop® 5-year clinical…

The 5 year and end of study results show: The 5 year and end of study results show: In addition to publication inSurgical Endoscopy, this study titled, 'Food passageway-related sequelae in the RefluxStop prospective multicenter trial: Patient-centric outcomes of dysphagia, odynophagia, gas-bloating, and inability to belch and/or vomit at 5 years', was the subject of a very successful SAGES 2025 ( California, USA ) oral presentation by Dr. med. Jörg Zehetner of Kinik Beau-SiteBern,...
PR Newswire
01/07/2025

ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits…

FDA 510(k) application submitted to allow marketing of the ARC-EX ®System for home use in the United StatesCE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European Union and other countriesEINDHOVEN, the Netherlands, July01, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with...
Nasdaq GlobeNewswire
01/07/2025

CentraLlVF Launches New Guaranteed Egg Donation Programs Through CEB and AWEB

Designed specifically for the Australian market, these new offerings aim to meet the full range of clinical and financial needs of intended parents across the country. Designed specifically for the Australian market, these new offerings aim to meet the full range of clinical and financial needs of intended parents across the country. Through AWEB, CentraLlVF has introduced two new programs: 7 eggs with a guaranteed 1 blastocyst 8 eggs with a guaranteed 1 blastocyst These...
PR Newswire
01/07/2025

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast…

Key Takeaways from the GPCR-Targeting Therapies Market Report Key Takeaways from the GPCR-Targeting Therapies Market Report Discover which indication is expected to grab the major GPCR-targeting therapies market share @ GPCR-Targeting Therapies Market Report GPCR-Targeting Therapies Market Dynamics The GPCR-targeting therapies market is experiencing dynamic growth, driven byadvances in drug discovery technologies, anexpanding understanding of GPCR biology, and the...
PR Newswire
30/06/2025

Announcement of fully underwritten rights issue

- Final Phase 1 ovarian data: Final data read-out from the Phase 1 trial at 24 months follow-up. The final data will include 10 patients and is expected during H2 2025 - Final Phase 1 ovarian data: Final data read-out from the Phase 1 trial at 24 months follow-up. The final data will include 10 patients and is expected during H2 2025 - Complete Phase 2 recruitment: Completion of recruitment (96 patients) for the randomized controlled phase 2 trial in peritoneal metastases originating from...
PR Newswire
30/06/2025

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting…

This report provides a comprehensive analysis of the global market for cancer therapeutics. It covers the history, forms, pathophysiology, stages, and mechanisms of cancer metastasis and recurrence. The report also examines the disease burden through cancer epidemiology. It discusses various treatment patterns, including non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, chemotherapy, combinatorial therapy) approaches. This report...
PR Newswire
30/06/2025

Marine Collagen Market to Reach $2.32 Billion by 2032, Driven by Cosmetics…

Market Segmentation Highlights: Market Segmentation Highlights: By Type: To explore the complete report, visit:https://www.meticulousresearch.com/product/marine-collagen-market-5995 By Category: By Source: By Application Analysis: Regional Market Leadership: Key Market Drivers: Emerging Market Opportunities: For more comprehensive insights, download the FREE report sample:https://www.meticulousresearch.com/request-sample-report/cp_id=5995 ...
PR Newswire
30/06/2025

Transactions under Novonesis’ share buyback program

Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated 1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025.Please read the full announcement in PDF. Attachment 2025_35_Share_buyback_program
Nasdaq GlobeNewswire
30/06/2025

Wingderm USA Takes the Lead at TAS 2025, Cementing Its Local Presence in the…

The two featured energy-based devices meet the needs of North American practitioners for non-invasive treatments and suitability across diverse skin tones. Both have received FDA clearance, which helps build trust and supports their acceptance in the U.S. market. The FDA clearance not only affirms Wingderm®'s technology, but also lays the foundation for serving clients and building long-term operations in the U.S. market. The two featured energy-based devices meet the needs of North American...
PR Newswire
30/06/2025

Regenerative Medicine Market to Reach $45.66 Billion by 2032, Growing at a CAGR…

The growth of the regenerative medicine market is driven by factors such as increasing approvals for regenerative medicine, advancements in regenerative medicine technologies, the rising incidence of chronic health conditions, increasing therapeutic applications of regenerative medicine, and increasing R&D funding in regenerative medicine. The market's expansion is fueled by the growing demand for personalized medicine, the soaring need for healthy organs for transplant, and the rising…
PR Newswire
30/06/2025

Rapid Diagnostics Market to Reach $24.28 Billion by 2032, Growing at a CAGR of…

The growth of the rapid diagnostics market is driven by increasing demand for point-of-care (POC) diagnostics, the rising prevalence of chronic diseases alongside an aging population, the need for swift decision-making in emergency departments, and ongoing technological innovations. The market's expansion is fueled by the growing necessity for early disease detection, enhanced diagnostic accessibility, and the integration of smartphone-based diagnostic platforms across global healthcare systems.
PR Newswire
30/06/2025

IBA – Transparency Notification - Denominator

June 30 th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision: « [...] the issuer publishes the total capital, the total number of...
Nasdaq GlobeNewswire
30/06/2025

OSE Immunotherapeutics Publishes Letter to Shareholders

OSE Immunotherapeutics Publishes Letter to ShareholdersNANTES, France, June 30, 2025, 6:00 p.m. - OSE ImmunotherapeuticsSA(ISIN: FR0012127173; Mnemo: OSE), announces the publication of its inaugural Letter to Shareholders.The Company’s CEO and Board of Directors wish to share with shareholders the key achievements of recent months, the foundations of its growth strategy and perspectives for the future.The Letter to Shareholders is available on the Company's website:...
Nasdaq GlobeNewswire
30/06/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – June 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 26, 2025, from Atlas Special…
Actusnews Wire
30/06/2025

EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27…

Press Release Paris – June 30, 2025– EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with a simultaneous closing to Particle Dynamics - a global leader in particle processing, delivery technologies, and finished dose manufacturing for the nutraceutical, consumer health, and pharmaceutical sectors.“The divestment of Haverhill is a key step toward...
Nasdaq GlobeNewswire
30/06/2025

In Vitro Diagnostics (IVD) Market to Reach $123.28 Billion by 2032, Growing at a…

The growth of the IVD market is driven by the rising prevalence of chronic diseases, increasing occurrence of infectious diseases, growing awareness of the importance of early disease diagnosis, increasing demand for point-of-care (POC) diagnostic and rapid diagnostic solutions, rising healthcare expenditures, and increasing investments in research and development. The market's expansion is fueled by technological advancements in molecular diagnostics, artificial intelligence integration…
PR Newswire
30/06/2025

Metagenomics Market to Reach $7.78 Billion by 2032, Growing at a CAGR of 15.8%…

The significant growth of the metagenomics market is driven by rapidly decreasing sequencing costs making genomic research more accessible, increasing focus on agricultural genomics for crop improvement and sustainable farming, expansion of the food and beverage industry requiring advanced microbial analysis, and the surge in large-scale genome mapping programs worldwide. The market's expansion is fueled by rising adoption of bioinformatics and genomic data management solutions, government…
PR Newswire
30/06/2025

Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s…

Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics The oversubscribed round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with substantial participation from existing investors SCVC, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank and WS Investment Company (Wilson Sonsini’s venture arm). Proteins...
Nasdaq GlobeNewswire
30/06/2025
Altri  Comunicati